Approved to ass introgram of a program of the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTC-0.1901)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 4 of 4

PATENT NO. : 7,169,127 B2 APPLICATION NO.: 10/078,676

ISSUE DATE : January 30, 2007
INVENTOR(S) : Epstein et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 11, lines 2-3 (column 10, lines 63-64), "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to --polysaccharides, cellulose, hydrogels, aliginate, or combinations--:

Claim 13, line 3 (column 11, line 3), "channel, and a injection" should be changed to -channel and an injection-;

Claim 13, lines 8-9 (column 11, lines 8-9), "materia; and" should be changed to -material; and--;

Claim 19, line 4 (column 12, line 4), "catheter" should be changed to -a catheter --;

Claim 19, lines 5-6 (column 12, lines 5-6), "pressure" and "apron slidable on the catheter; and" should be on the same line:

Claim 19, line 9 (column 12, line 9), "surfaces," should be changed to -surface, --; and

Claim 22, lines 1-2 (column 12, lines 22-23), "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to --polysaccharides, cellulose, hydrogels, alginate, or combinations--.

In Fig. 4B, reference numeral "480" pointing to the arrow should be removed since reference number 480 is already used to designate a different element in Figure 4B.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON 1500 K Street, N.W., Suite 700 Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO) to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is entitled to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, studied be sent to the information of the comment of the property of the proper

Serial No. 10/078,676 Docket No. 12013/62001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Samuel J. Epstein, et al.

SERIAL NO. : 10/078,676

PATENT NO. : 7,169,127 B2

FILED : January 30, 2007

FOR : PRESSURE APRON DIRECT INJECTION CATHETER

GROUP ART UNIT: 3763 CONFIRMATION NO: 4788

EXAMINER : Chris Loiren Rodriguez

Attn: Certificate of Corrections Branch

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 C.F.R. § 1.322 and/or 37 C.F.R. § 1.323

SIR:

Patentee hereby requests that the enclosed Certificate of Correction be issued for the above Patent under 37 C.F.R. § 1.322 and/or 37 C.F.R. § 1.323.

USPTO ERRORS

The following errors were mistakes made by the Patent and Trademark Office and did not occur through applicant error. Correction thereof does not involve changes in the patent as would constitute new matter or would require reexamination. In particular:

On the Front Page:

According to the Bibliographic Data Sheet of August 17, 2006, "Samuel J. Epstein, Lynnfield, MA" should be changed to --Samuel J. Epstein, Newton, MA-.

In the Specification:

Column 4, line 55, "throbin and fibrinigen" should be changed to -thrombin and fibrinogen--;

Serial No. 10/078,676 Docket No. 12013/62001

Column 4, line 66-67, "glycosanilono glycans" should be changed to --glycosamino glycans--;

Column 5, line 15, "haparmn" should be changed to -heparin--;

Column 5, line 55, "thereof Myoblasts," should be changed to -thereof. Myoblasts, --;

Column 5, line 66, "RINA" should be changed to -RNA--;

Column 9, line 54, "Razor blade" should be changed to -Using a razor blade--; and

Column 9, line 60, "PBS:" should be changed to -PBS .--.

In the Claims:

Claim 13, lines 8-9 (column 11, lines 8-9), "materia; and" should be changed to -material; and--;

Claim 19, line 4 (column 12, line 4), "catheter" should be changed to -a catheter--;

Claim 19, lines 5-6 (column 12, lines 5-6), "pressure" and "apron slidable on the catheter; and" should be on the same line; and

Claim 19, line 9 (column 12, line 9), "surfaces," should be changed to -surface, --.

These correct phrases can be found in the original specification or in Amendments to the Specification, submitted October 14, 2003, or the Amendments to the Claims submitted on June 5, 2006 by Applicant during prosecution. Because this error was a mistake by the Patent and Trademark Office, no fee is required.

APPLICANTS ERRORS

The following errors that appear in this patent are of a clerical, typographical or minor nature or character and occurred in good faith. Correction thereof does not involve changes in the patent as would constitute new matter or would require reexamination. In particular:

On the Front Page:

Abstract, line 1, "for insitu plug" should be changed to -for in-situ plug--;

In the Specification:

Column 2, line 7, "line 2-2" should be changed to -line II-II-:

Column 2, line 18, "line 6—6" should be changed to -line IV—IV--;

Column 2, line 51, "before hand" should be changed to -beforehand--;

Column 2, line 59, "as well being one of numerous" should be changed to -as well as numerous--:

Column 3, line 1, "suitbly" should be changed to -suitably --;

Column 3, line 32, "line 2-2" should be changed to -line II-II-:

Column 3, line 23-24, "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to --polysaccharides, cellulose, hydrogels, aliginate, or combinations--:

Column 3, line 38, "obround" should be changed to -or round--;

Column 4, line 15, "tissue an adhesive" should be changed to -tissue, an adhesive--:

Column 4, line 37, "preferrable" should be changed to -preferable--;

Column 4, line 48, "be a in polymer solution" should be changed to -be in a polymer solution--:

Column 5, line 42, "promotors" should be changed to -promoters--;

Column 5, line 44, "promotors" should be changed to -promoters--;

Column 5, line 52, "endogeneus vascoactive" should be changed to -endogenous vasoactive--:

Column 6, line 28, "("BMP's")" should be changed to --("BMPs")--;

Column 6, line 32, "BMP's" should be changed to -BMPs--;

Column 7, line 5, "larger side of the pressure apron 430" should be changed to larger side 460 of the pressure apron 430—to be consistent with Fig.4A;

Column 7, line 7-8, "catheter 470 with the first channel" should be changed to --catheter 470 with catheter wall 450 and the first channel—to be consistent with Fig. 4A;

Column 7, lines 11-12, "void 470" should be changed to -void 475--;

Column 7, line 12, "seen the" should be changed to -seen, the --;

Column 7, line 36, "500" should be deleted as it is not shown in the Figures;

Column 7, lines 39-40, "514 and 515." Should be changed to -514 and 515 separated by wall 525.— to be consistent with Fig. 5 and Fig. 6.

Column 7, line 56, "moveable" should be changed to --movable--;

Column 7, line 66, "set up therapeutic" should be changed to -set up, therapeutic--;

Column 8, line 5, "formed the" should be changed to -formed, the -:

Column 8, line 17, "line 6-6" should be changed to -line IV-IV--:

Column 8, line 30 "side an" should be changed to -side and--;

Column 8, line 53-54, "be plausible method" should be changed to -be a plausible method--:

Column 8, line 60, "(ug)" should be changed to -(µg)--;

Column 8, line 62, "ug" should be changed to -ug-;

Column 9, line 2, "Ca2+" should be changed to --Ca2+--;

Column 9, line 3, "ug" should be changed to -μg--;

Column 9, line 5, "ug" should be changed to -μg--;

Column 9, line 10, "the expected." should be changed to -the expected concentration.--;

Column 9, line 15, "3." should be deleted;

Column 9, line 16, "4." should be deleted;

Column 9, line 18, "5." should be deleted;

Column 9, line 22, "6." should be deleted;

Column 9, line 24, "7." should be changed to -3.--;

Column 9, line 38, "uL" should be changed to -µL--;

Column 9, line 39, "uL" should be changed to -µL--;

Column 9, line 46, both instances of "uL" should be changed to -µL--;

Column 9, line 63, "flourometry." should be changed to -fluorometry .--; and

Column 9, line 66, "Multiplying" should be changed to -Multiply--.

In the Claims:

Claim 11, lines 2-3 (column 10, lines 63-64), "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to --polysaccharides, cellulose, hydrogels, alginate, or combinations--;

Claim 13, line 3 (column 11, line 3), "channel, and a injection" should be changed to – channel and an injection—; and

Claim 22, lines 1-2 (column 12, lines 22-23), "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to --polysaccharides, cellulose, hydrogels, alginate, or combinations--.

Serial No. 10/078,676 Docket No. 12013/62001

In the Figures:

In Fig. 4B, reference numeral "480" pointing to the arrow should be removed since reference number 480 is already used to designate a different element in Figure 4B.

Conclusion

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.20(a) Certificate of Correction fee of \$100.00 to the deposit account of Kenyon & Kenyon, deposit account number 11-0600. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Dated: June 25, 2008 /Jocelyn D. Ram/

Jocelyn D. Ram Reg. No. 54,898

KENYON AND KENYON LLP 1500 K Street, N.W. - Suite 700 Washington, D.C. 20005-1257 Tel: 202 220-4200

Fax: 202 220-4201

U.S. Patent and TrademAt Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTC-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

	Page	1	of	4
--	------	---	----	---

PATENT NO. : 7,169,127 B2

APPLICATION NO.: 10/078,676

ISSUE DATE : January 30, 2007

Epstein et al.

INVENTOR(S)

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

"Samuel J. Epstein, Lynnfield, MA" should be changed to --Samuel J. Epstein, Newton, MA--. Abstract, line 1, "for insitu plug" should be changed to -for in-situ plug--:

Column 2, line 7, "line 2-2" should be changed to -line II--II--;

Column 2, line 18, "line 6—6" should be changed to –line IV—IV--;

Column 2, line 51, "before hand" should be changed to -beforehand --:

Column 2, line 59, "as well being one of numerous" should be changed to -as well as numerous--;

Column 3, line 1, "suitbly" should be changed to -suitably--;

Column 3, line 32, "line 2-2" should be changed to -line II--II--;

Column 3, line 23-24, "polysacharides, cellulose, hydrogels, aliginate, or combinations" should be changed to

--polysaccharides, cellulose, hydrogels, alginate, or combinations--;

Column 3, line 38, "obround" should be changed to -or round--;

Column 4, line 15, "tissue an adhesive" should be changed to -tissue, an adhesive--;

Column 4, line 37, "preferrable" should be changed to -preferable--;

Column 4, line 48, "be a in polymer solution" should be changed to -be in a polymer solution--;

Column 4, line 55, "throbin and fibringen" should be changed to -thrombin and fibringen--;

Column 4, line 66-67, "glycosanilono glycans" should be changed to --glycosamino glycans--;

Column 5, line 15, "haparmn" should be changed to -heparin--;

Column 5, line 42, "promotors" should be changed to -promoters--;

Column 5, line 44, "promotors" should be changed to -promoters--;

Column 5, line 52, "endogeneus vascoactive" should be changed to -endogenous vasoactive--;

Column 5, line 55, "thereof Myoblasts," should be changed to -thereof. Myoblasts, --:

Column 5, line 66, "RINA" should be changed to -RNA--;Column 6, line 28, "("BMP's")" should be changed to --("BMPs")--:

Column 6, line 32, "BMP's" should be changed to -BMPs--:

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON 1500 K Street, N.W., Suite 700

Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to late 1.0 hour to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual cases. Any comments on the anount of time you require to complete the form and/or suggestions for reducing this burdon, should be sent to the information Cfficer. US. Department of Commence, P.O. Box 1450, Abscandina, VA. 22313-1450, DO NOT 3210 PEEC OF CONFILETED C

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also From PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 4

PATENT NO. : 7,169,127 B2

APPLICATION NO.: 10/078,676

ISSUE DATE : January 30, 2007

INVENTOR(S) : Epstein et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 7, line 5, "larger side of the pressure apron 430" should be changed to larger side 460 of the pressure apron 430—to be consistent with Fig.4A;

Column 7, line 7-8, "catheter 470 with the first channel" should be changed to --catheter 470 with catheter wall 450 and the first channel—to be consistent with Fig. 4A:

Column 7, lines 11-12, "void 470" should be changed to -void 475--;

Column 7, line 12, "seen the" should be changed to -seen, the --;

Column 7, line 36, "500" should be deleted as it is not shown in the Figures:

Column 7, lines 39- 40, "514 and 515." Should be changed to -514 and 515 separated by wall 525.— to be consistent with Fig. 5 and Fig. 6.

Column 7, line 56, "moveable" should be changed to --movable--:

Column 7, line 66, "set up therapeutic" should be changed to -set up, therapeutic--;

Column 8, line 5, "formed the" should be changed to -formed, the--;

Column 8, line 17, "line 6—6" should be changed to –line IV—IV--:

Column 8, line 30 "side an" should be changed to –side and--:

Column 8, line 53-54, "be plausible method" should be changed to -be a plausible method--;

Column 8, line 60, "(ug)" should be changed to -(µg)--;

Column 8, line 62, "ug" should be changed to -µg--; Column 9, line 2, "Ca2+" should be changed to --Ca2+--;

Column 9, line 3, "ua" should be changed to -ua--:

Column 9, line 5, "ug" should be changed to -µg--;

Column 9, line 10, "the expected," should be changed to -the expected concentration. --;

Column 9, line 15, "3." should be deleted;

Column 9, line 16, "4," should be deleted:

Column 9, line 18, "5." should be deleted;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON 1500 K Street, N.W., Suite 700

Washington, D.C. 20005

This collection of information is required by 37 CPR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 3 S U.S. C. 122 and 37 CPR 1.14. This collection is either to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual cases. Any comments on the anount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the information Cfficer. U.S. Patert and Tracterian Cfficer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DC NOT SEND PEEC OR COMPLETED VA 2211-146 ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2213-1450.

Approved for use through 04/30/2007. OMB 0093-10033

U.S. Patent and Trademank Office; U.S. DIMENTO FOOMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTAL-1950)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page		4
	of	

PATENT NO. : 7,169,127 B2 APPLICATION NO.: 10/078,676

ISSUE DATE : January 30, 2007

NVENTOR(S) : Epstein et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 9, line 22, "6." should be deleted;

Column 9, line 24, "7," should be changed to -3,--:

Column 9, line 16, "4." should be deleted;

Column 9, line 18, "5." should be deleted; Column 9, line 22, "6." should be deleted;

Column 9, line 24, "7." should be changed to -3.--:

Column 9, line 38, "uL" should be changed to –uL--;

Column 9, line 38, "uL" should be changed to –µL--; Column 9, line 39, "uL" should be changed to –µL--;

Column 9, line 46, both instances of "uL" should be changed to -uL--;

Column 9, line 54, "Razor blade" should be changed to -Using a razor blade--:

Column 9, line 60, "PBS:" should be changed to -PBS.—

Column 9, line 63, "flourometry," should be changed to -fluorometry,--: and

Column 9, line 66, "Multiplying" should be changed to -Multiply--:

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON 1500 K Street, N.W., Suite 700

Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO) to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is entitled to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, studied be sent to the information of the comment of the property of the proper